Clovis Oncology, a commercial-stage biotechnology company founded in 2009, is dedicated to advancing the fight against cancer. The company's focus on acquiring, developing, and commercializing cancer treatments in the United States, Europe, and other international markets demonstrates its commitment to improving the lives of cancer patients. The core of Clovis Oncology's approach lies in precision medicine, aiming to deliver the right drug to the right patient at the right time, thus shaping the future of cancer therapy. Their product development programs target specific subsets of cancer, and they collaborate with partners to develop diagnostic tools intended to direct a compound to the patients most likely to benefit. This approach underscores their commitment to personalized treatment solutions. With its management team's extensive experience in developing novel cancer therapies, Clovis Oncology is well-positioned to make meaningful improvements in patients' lives. Headquartered in Boulder, Colorado, Clovis Oncology's most recent Venture Round investment was on 02 June 2011, with Pfizer Venture Investments as the investor. This signifies a vote of confidence from a prominent investor in the company's vision and potential within the biopharma industry. For more information about Clovis Oncology and its activities, interested individuals can refer to the company's official website.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 | Pfizer Venture Investments | 02 Jun 2011 |
| Venture Round | $145.00M | 7 |
|
21 May 2009 |
No recent news or press coverage available for Clovis Oncology.
We care about your data, and we'd love to use cookies make your experience better.
